Suzanne Egyhazi Brage

About me
Publications
Grants
Public outreach and news

About me

I have a PhD in experimental oncology. My main focus is to find novel
biomarkers for durable benefit from targeted therapies and immunotherapies
and novel targets to overcome drug resistance in cutaneous malignant
melanoma.

Articles

Article: IMMUNO-ONCOLOGY AND TECHNOLOGY. 2024;22:100713
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study.
Costa Svedman F; Liapi M; Månsson-Broberg A; Chatzidionysiou K; Egyhazi Brage S
Article: ACTA ONCOLOGICA. 2023;62(12):1921-1930
Radiotherapy with or without immunotherapy in metastatic melanoma: efficacy and Tolerability
Backlund E; Grozman V; Brage SE; Lewensohn R; Lindberg K; Helgadottir H
Article: CANCERS. 2022;14(15):3587
Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hoiom V; Brage SE
Article: CANCERS. 2022;14(3):702
Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors
Costa Svedman F; Jalsenius M; Hoeiom V; Grozman V; Bergqvist M; Soederdahl F; Eriksson H; Rotstein S; Ny L; Ascierto PA; Brage SE; Helgadottir H
Article: ACTA ONCOLOGICA. 2022;61(1):14-21
A biomarker panel predicts recurrence-free survival in ulcerated primary cutaneous melanoma
Falkenius J; Keskitalo J; Kanter L; Johansson H; Hoiom V; Hansson J; Brage SE
Article: GENETICS IN MEDICINE. 2022;24(1):157-169
Novel loss-of-function variant in DENND5A impedes melanosomal cargo transport and predisposes to familial cutaneous melanoma
Yang M; Johnsson P; Brautigam L; Yang XR; Thrane K; Gao J; Tobin NP; Zhou Y; Yu R; Nagy N; Engstrom PG; Tuominen R; Eriksson H; Lundeberg J; Tucker MA; Goldstein AM; Egyhazi-Brage S; Zhao J; Cao Y; Hoiom V
Article: SCIENTIFIC REPORTS. 2021;11(1):11023
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jonsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grander D; Brage SE; Johnsson P
Article: CANCER RESEARCH. 2021;81(9):2545-2555
Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy
Karlsson MJ; Svedman FC; Tebani A; Kotol D; Hoiom V; Fagerberg L; Edfors F; Uhlen M; Brage SE; Maddalo G
Article: CELL DEATH AND DISEASE. 2020;11(10):882
Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma
Das I; Chen H; Maddalo G; Tuominen R; Rebecca VW; Herlyn M; Hansson J; Davies MA; Brage SE
Article: MELANOMA RESEARCH. 2020;30(5):443-454
Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib
Vidarsdottir L; Fernandes RV; Zachariadis V; Das I; Edsbacker E; Sigvaldadottir I; Azimi A; Hoiom V; Hansson J; Grander D; Egyhazi Brage S; Pokrovskaja Tamm K
Article: CELL DEATH AND DIFFERENTIATION. 2020;27(7):2081-2098
AXL and CAV-1 play a role for MTH1 inhibitor TH1579 sensitivity in cutaneous malignant melanoma
Das I; Gad H; Braeutigam L; Pudelko L; Tuominen R; Hoiom V; Almlof I; Rajagopal V; Hansson J; Helleday T; Brage SE; Berglund UW
Article: CELL DEATH AND DISEASE. 2019;10(9):663
Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status
Das I; Wilhelm M; Hoiom V; Marquez RF; Svedman FC; Hansson J; Tuominen R; Brage SE
Article: MOLECULAR SYSTEMS BIOLOGY. 2018;14(3):e7858
Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
Azimi A; Caramuta S; Seashore-Ludlow B; Bostrom J; Robinson JL; Edfors F; Tuominen R; Kemper K; Krijgsman O; Peeper DS; Nielsen J; Hansson J; Brage SE; Altun M; Uhlen M; Maddalo G
Article: BRITISH JOURNAL OF CANCER. 2018;118(4):480-488
Immune gene expression and response to chemotherapy in advanced breast cancer
Foukakis T; Lovrot J; Matikas A; Zerdes I; Lorent J; Tobin N; Suzuki C; Brage SE; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Ferno M; Skoog L; Bergh J; Hatschek T
Article: PLOS ONE. 2018;13(11):e0206942
Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
Article: CELLULAR ONCOLOGY (DORDRECHT). 2017;40(6):631-638
ΔNp73 regulates the expression of the multidrug-resistance genes ABCB1 and ABCB5 in breast cancer and melanoma cells - a short report
Sakil HAM; Stantic M; Wolfsberger J; Brage SE; Hansson J; Wilhelm MT
Article: CELL DEATH AND DISEASE. 2017;8(8):e3029
Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells
Azimi A; Tuominen R; Svedman FC; Caramuta S; Pernemalm M; Stolt MF; Kanter L; Kharaziha P; Lehtio J; Johansson CH; Holom V; Hansson J; Brage SE
Article: BMC CANCER. 2017;17(1):584
Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma
Falkenius J; Johansson H; Tuominen R; Stolt MF; Hansson J; Brage SE
Article: ONCOTARGET. 2017;8(13):21539-21553
Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma
de Coana YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nystrom M; Edback U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Article: CELL REPORTS. 2016;15(9):2000-2011
Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis
Georgoudaki A-M; Prokopec KE; Boura VF; Hellqvist E; Sohn S; Ostling J; Dahan R; Harris RA; Rantalainen M; Klevebring D; Sund M; Brage SE; Fuxe J; Rolny C; Li F; Ravetch JV; Karlsson MCI
Article: CLINICAL CANCER RESEARCH. 2016;22(1):146-157
Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer
Kimbung S; Johansson I; Danielsson A; Veerla S; Brage SE; Stolt MF; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmstrom P-O; Soderberg M; Walz TM; Ferno M; Hatschek T; Hedenfalk I
Article: INTERNATIONAL JOURNAL OF CANCER. 2015;136(12):2844-2853
MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma
Tuominen R; Jewell R; van den Oord JJ; Wolter P; Stierner U; Lindholm C; Johansson CH; Linden D; Johansson H; Stolt MF; Walker C; Snowden H; Newton-Bishop J; Hansson J; Brage SE
Article: ANNALS OF ONCOLOGY. 2015;26(1):81-88
Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival
Tobin NP; Harrell JC; Lövrot J; Egyhazi Brage S; Frostvik Stolt M; Carlsson L; Einbeigi Z; Linderholm B; Loman N; Malmberg M; Walz T; Fernö M; Perou CM; Bergh J; Hatschek T; Lindström LS
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2014;24(8):1389-1394
Metabolic Markers and HSP60 in Chemonaive Serous Solid Ovarian Cancer Versus Ascites
Hjerpe E; Brage SE; Stolt MF; Johansson H; Shoshan M; Avall-Lundqvist E
Article: MATRIX BIOLOGY. 2014;38:69-83
Laminins 411 and 421 differentially promote tumor cell migration via α6β1 integrin and MCAM (CD146)
Ishikawa T; Wondimu Z; Oikawa Y; Gentilcore G; Kiessling R; Brage SE; Hansson J; Patarroyo M
Article: BRITISH JOURNAL OF CANCER. 2014;110(10):2489-2495
Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance
Azimi A; Pernemalm M; Stolt MF; Hansson J; Lehtio J; Brage SE; Johansson CH
Journal article: ANNALS OF ONCOLOGY. 2014;25:i5
12O Molecular Subtype of Breast Cancer Metastases Significantly Influences Patient Post-Relapse Survival
Tobin NP; Harrell JC; Brage SE; Stolt MF; Perou CM; Bergh J; Hatschek T; Lindström LS
Article: MELANOMA RESEARCH. 2013;23(6):452-460
High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma
Falkenius J; Lundeberg J; Johansson H; Tuominen R; Frostvik-Stolt M; Hansson J; Brage SE
Article: BMC CLINICAL PATHOLOGY. 2013;13(1):30
Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer.
Hjerpe E; Egyhazi Brage S; Carlson J; Frostvik Stolt M; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Article: MELANOMA RESEARCH. 2013;23(5):360-365
Association of MITF and other melanosome-related proteins with chemoresistance in melanoma tumors and cell lines
Johansson CH; Azimi A; Stolt MF; Shojaee S; Wiberg H; Grafstrom E; Hansson J; Brage SE
Article: CANCER RESEARCH. 2013;73(13):3877-3887
Melanoma-Educated CD14⁺ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2-Dependent Mechanisms
Mao Y; Poschke I; Wennerberg E; de Coana YP; Brage SE; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Article: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER. 2013;23(3):448-455
HSP60 Predicts Survival in Advanced Serous Ovarian Cancer
Hjerpe E; Egyhazi S; Carlson J; Stolt MF; Schedvins K; Johansson H; Shoshan M; Avall-Lundqvist E
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(12):2809-2817
High Frequency of p16 ^INK4A Promoter Methylation in NRAS-Mutated Cutaneous Melanoma
Jonsson A; Tuominen R; Grafstrom E; Hansson J; Egyhazi S
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(8):2062-2070
MicroRNA Expression Profiles Associated with Mutational Status and Survival in Malignant Melanoma
Caramuta S; Egyhazi S; Rodolfo M; Witten D; Hansson J; Larsson C; Lui W-O
Article: CANCER IMMUNOLOGY, IMMUNOTHERAPY. 2009;58(7):1085-1094
Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma
Johansson CC; Egyhazi S; Masucci G; Harlin H; Mougiakakos D; Poschke I; Nilsson B; Garberg L; Tuominen R; Linden D; Stolt MF; Hansson J; Kiessling R
Article: PIGMENT CELL AND MELANOMA RESEARCH. 2009;22(2):196-204
MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters
Hoiom V; Tuominen R; Kaller M; Linden D; Ahmadian A; Mansson-Brahme E; Egyhazi S; Sjoberg K; Lundeberg J; Hansson J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(4):526-534
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer
Baselga J; Zambetti M; Llombart-Cussac A; Manikhas G; Kubista E; Steger GG; Makhson A; Tjulandin S; Ludwig H; Verrill M; Ciruelos E; Egyhazi S; Xu L-A; Zerba KE; Lee H; Clark E; Galbraith S
Article: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2008;128(11):2696-2704
Lack of Cytoplasmic ERK Activation Is an Independent Adverse Prognostic Factor in Primary Cutaneous Melanoma
Jovanovic B; Kroeckel D; Linden D; Nilsson B; Egyhazi S; Hansson J
Article: MOLECULAR CANCER THERAPEUTICS. 2008;7(9):2876-2883
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Smalley KSM; Lioni M; Palma MD; Xiao M; Desai B; Egyhazi S; Hansson J; Wu H; King AJ; Van Belle P; Elder DE; Flaherty KT; Herlyn M; Nathanson KL
Article: CANCER RESEARCH. 2007;67(19):9006-9012
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dofou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Article: MELANOMA RESEARCH. 2006;16(6):471-478
NRAS and BRAF mutations in melanoma turnours in re ation to clinical characteristics:: a study based on mutation screening by pyrosequencing
Edlundh-Rose E; Egyhazi S; Omholt K; Mansson-Brahme E; Platz A; Hansson J; Lundeberg J
Article: CLINICAL CHEMISTRY. 2005;51(12):2388-2391
Detection of MC1R polymorphisms with protease-mediated allele-specific extension as an alternative to direct sequencing
Käller M; Tuominen R; Ahmadian A; Magnusson V; Egyhazi S; Hansson J; Lundeberg J
Article: CLINICAL CANCER RESEARCH. 2005;11(8):2991-2997
Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival
Grafström E; Egyházi S; Ringborg U; Hansson J; Platz A
Article: BREAST CANCER RESEARCH. 2005;7(6):R953-R964
Gene expression profiling spares early breast cancer patients from adjuvant therapy:: derived and validated in two population-based cohorts
Pawitan Y; Bjöhle J; Amler L; Borg AL; Egyhazi S; Hall P; Han X; Holmberg L; Huang F; Klaar S; Liu ET; Miller L; Nordgren H; Ploner A; Sandelin K; Shaw PM; Smeds J; Skoog L; Wedrén S; Bergh J
Article: BRITISH JOURNAL OF CANCER. 2003;89(8):1517-1523
O⁶-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma
Ma S; Egyházi S; Ueno T; Lindholm C; Kreklau EL; Stierner U; Ringborg U; Hansson J
Article: HUMAN MUTATION. 2002;20(5):408-409
Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden.
Egyházi S; Ma S; Smoczynski K; Hansson J; Platz A; Ringborg U
Article: ONCOLOGY REPORTS. 2002;9(5):1015-1019
Immunohistochemical analysis of DNA mismatch repair protein and O⁶-methylguanine-DNA methyltransferase in melanoma metastases in relation to clinical response to DTIC-based chemotherapy
Ma S; Egyházi S; Ringborg U; Hansson J
Article: MELANOMA RESEARCH. 2002;12(4):335-342
Analysis of O⁶-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy
Ma S; Egyházi S; Martenhed G; Ringborg U; Hansson J
Article: CARCINOGENESIS. 1997;18(10):1889-1895
O-6-methylguanine-DNA methyltransferase activity in human buccal mucosal tissue and cell cultures. Complex mixtures related to habitual use of tobacco and betel quid inhibit the activity in vitro
Liu Y; Egyhazi S; Hansson J; Bhide SV; Kulkarni PS; Grafstrom RC
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(3):447-452
Role of O-6-methylguanine-DNA methyltransferase, glutathione transferase M3-3 and glutathione in resistance to carmustine in a human non-small cell lung cancer cell line
Egyhazi S; Edgren MR; Hansson J; Krockel D; Mannervik B; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1997;33(1):129-134
Immunohistochemical examination of the expression of O-6-methylguanine-DNA methyltransferase in human melanoma metastases
Egyhazi S; Margison GP; Hansson J; Ringborg U
Article: EUROPEAN JOURNAL OF CANCER. 1996;32A(13):2319-2326
Analysis of O-6 methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction
Hansson J; Martenhed G; Egyhazi S; Tani E; Platz A
Article: ACTA ONCOLOGICA. 1996;35(6):683-690
Increased cisplatin sensitivity of human fibroblasts from a subject with inherent glutathione deficiency
Hansson J; Edgren MR; Egyhazi S; Hao XY; Mannervik B; Ringborg U
Article: ANTI-CANCER DRUGS. 1995;6(5):657-668
APOPTOSIS AND C-JUN INDUCTION BY CISPLATIN IN A HUMAN-MELANOMA CELL-LINE AND A DRUG-RESISTANT DAUGHTER CELL-LINE
ZHAO R; RABO YB; EGYHAZI S; ANDERSSON A; EDGREN MR; LINDER S; HANSSON J
Journal article: CANCER RESEARCH. 1993;53(18):4257-4261
CONTRIBUTION OF GLUTATHIONE TRANSFERASE M3-3 TO 1,3-BIS(2-CHLOROETHYL)-1-NITROSOUREA RESISTANCE IN A HUMAN NONSMALL CELL LUNG-CANCER CELL-LINE
BERHANE K; HAO XY; EGYHAZI S; HANSSON J; RINGBORG U; MANNERVIK B
Journal article: EUROPEAN JOURNAL OF CANCER. 1991;27(12):1658-1662
CARMUSTINE-INDUCED TOXICITY, DNA CROSS-LINKING AND O6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITY IN 2 HUMAN LUNG-CANCER CELL-LINES
EGYHAZI S; BERGH J; HANSSON J; KARRAN P; RINGBORG U
Show more

All other publications

Conference publication: ANNALS OF ONCOLOGY. 2023;34:s688-s689
Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Svedman FC; Liapi M; Chatzidionysiou A; Mansson-Broberg A; Brage SE
Letter: ACTA ONCOLOGICA. 2022;61(9):1116-1120
Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy
Costa Svedman F; Jalsenius M; Grozman V; Bergqvist M; Soderdahl F; Rotstein S; Ny L; Egyhazi Brage S; Helgadottir H
Meeting abstract: ANNALS OF ONCOLOGY. 2022;33(7):S945
Inflammation proteins associated with worse clinical outcome to treatment with anti-PD1 in metastatic cutaneous melanoma
Svedman FC; Helgadottir H; Brage SE
Letter: ACTA ONCOLOGICA. 2022;61(7):869-873
Precision radiation of immune checkpoint therapy resistant melanoma metastases (PROMMEL study): study protocol for a phase II open-label multicenter trial
Backlund E; Yang M; Grozman V; Masucci G; Falkenius J; Eriksson H; Jovanovic B; Hammarlund K; Isacsson U; Radu C; Abel E; Karlsson K; Palanco Zamora R; Wersall P; Edback U; Wickstrom S; Darai Ramqvist E; Egyhazi Brage S; Kiessling R; Viktorsson K; Franzen B; Lewensohn R; Olofsson Bagge R; Ullenhag GJ; Ny L; Lindberg K; Helgadottir H
Editorial comment: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2022;142(3 PT A):736-740.e6
Coexpression of MTH1 and PMS2 Is Associated with Advanced Disease and Disease Progression after Therapy in Melanoma
Das I; Tuominen R; Helleday T; Hansson J; Berglund UW; Brage SE
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(15):9556
Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.
Helgadottir H; Svedman FC; Jalsenius M; Hoiom V; Rotstein S; Brage SE; Grozman V; Soderdahl F; Ny L; Bergqvist M
Preprint: BIORXIV. 2020
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grandér D; Brage SE; Johnsson P
Conference publication: ANNALS OF ONCOLOGY. 2019;30:xi8-xi9
27P Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)
Svedman FC; Yang M; Tuominen R; Brage SE; Höiom V
Meeting abstract: ANNALS OF ONCOLOGY. 2019;30:vii8
Therapeutic implications of MTH1 inhibitor TH1579 in cutaneous malignant melanoma
Das I; Gad H; Brautigam L; Pudelko L; Tuominen R; Hoiom V; Almlof I; Hansson J; Helleday T; Brage SE; Berglund UW
Conference publication: ANNALS OF ONCOLOGY. 2019;30:v559
1369P Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hansson J; Höiom V; Brage SE
Meeting abstract: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2019;139(9):s298
Elucidate the underlying molecular mechanisms of the combination treatment effects of Afatinib (EGFR/HER2 inhibitor) and Crizotinib (MET inhibitor) in cutaneous malignant melanoma (CMM)
Das I; Chen H; Maddalo G; Wilhelm M; Tuominen R; Hoiom V; Hansson J; Davies M; Brage S
Conference publication: ANNALS OF ONCOLOGY. 2019;30
Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI)
Svedman FC; Yang M; Tuominen R; Brage SE; Holom V
Conference publication: ANNALS OF ONCOLOGY. 2019;30:559
Genes involved in DNA replication, chromatin remodeling and cell cycle as potential biomarkers for therapy outcome to immune therapy in patients with metastatic cutaneous malignant melanoma
Svedman FC; Das I; Tuominen R; Ramqvist ED; Hansson J; Hoiom V; Brage SE
Conference publication: CANCER IMMUNOLOGY RESEARCH. 2018;6(9):a14
Surgical removal of metastatic lesions increases T-cell reactivity to tumor-associated antigens in stage III melanoma patients
de Coana YP; Gunnarsdottir FB; Wolodarski M; Brage SE; Masucci G; Hansson J; Kiessling R
Meeting abstract: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2018;138(5):S200
Effects of MTH1 inhibitor TH1579 on cutaneous melanoma
Das I; Gad H; Pudelko L; Brautigam L; Tuominen R; Helleday T; Hansson J; Brage S; Berglund U
Conference publication: ANNALS OF ONCOLOGY. 2017;28:v437
1232P Investigation of AMBRA1 as a melanoma susceptibility gene
Hoeiom V; Yang M; Nosrati K; Azimi A; Brage SE; Tuominen R
Conference publication: CANCER RESEARCH. 2017;77:p1-07-16-p1-07-16
Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients
Tobin NP; Lundberg A; Lindstrom LS; Harrell JC; Brage SE; Stolt MF; Einbeigi Z; Loman N; Malmberg M; Perou CM; Bergh J; Hatschek T
Conference publication: ANNALS OF ONCOLOGY. 2017;28
Investigation of AMBRA1 as a melanoma susceptibility gene
Hoeiom V; Yang M; Nosrati K; Azimi A; Brage SE; Tuominen R
Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(9):s245
500 Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma
Lohcharoenkal W; Svedman FC; Sonkoly E; Brage SE; Hansson J; Pivarcsi A; Eriksson H
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):9579
Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma (CMM).
Eriksson H; Lohcharoenkal W; Costa-Svedman F; Sonkoly E; Brage SE; Hansson J; Pivarcsi A
Conference publication: CANCER RESEARCH. 2016;76:B28
PTENpg1 antisense RNA mediates PTEN suppression in vemurafenib resistance and predicts clinical outcome in melanoma patients
Vidarsdottir L; Azimi A; Serviss J; Ingvar C; Jonsson G; Olsson H; Stolt MF; Hansson J; Brage SE; Grander D; Johnsson P
Conference publication: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2016;136(9):S245
Exosomal microRNAs as putative predictive biomarkers for targeted therapy in stage IV cutaneous malignant melanoma
Lohcharoenkal W; Svedman FC; Sonkoly E; Brage SE; Hansson J; Pivarcsi A; Eriksson H
Conference publication: CANCER RESEARCH. 2015;75:p6-08-03-p6-08-03
Transcriptional profiling of breast cancer metastases identifies liver metastasis-selective genes associated with adverse outcome in luminal A primary breast cancer
Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi S; Bergh J; Einbeigi Z; Linderholm B; Lidbrlnk E; Loman N; Malmstroem P; Soederberg M; Walz TM; Fernoe M; Hatschek T; Hedenfalk I
Review: PHARMACOLOGY AND THERAPEUTICS. 2014;142(2):176-182
BRAF inhibitors in cancer therapy
Johansson CH; Brage SE
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2014;134(1):287-290
Somatic BRAF and NRAS Mutations in Familial Melanomas with Known Germline CDKN2A Status: A GenoMEL Study
Zebary A; Omholt K; van Doorn R; Ghiorzo P; Harbst K; Johansson CH; Hoiom V; Jonsson G; Pjanova D; Puig S; Scarra GB; Harland M; Olsson H; Brage SE; Palmer J; Kanter-Lewensohn L; Vassilaki I; Hayward NK; Newton-Bishop J; Gruis NA; Hansson J
Meeting abstract: EUROPEAN JOURNAL OF CANCER. 2012;48:43
Unraveling BRAF Inhibitor (PLX4032) Resistance Mechanisms
Azimi A; Johansson CH; Pernemalm M; Touminen R; Lehtio J; Hansson J; Egyhazi S
Conference publication: ANNALS OF ONCOLOGY. 2012;23:v27
P2.17 Proteomics and Gene Expression Profiling of Melanoma Chemotherapy Response in Tumors
Johansson CH; Azimi A; Pernemalm M; Pawitan Y; Stolt MF; Lazar V; Lundeberg J; Lehtiö J; Egyhazi S; Hansson J
Conference publication: ANNALS OF ONCOLOGY. 2012;23:v23
P2.04 Effects of Combined Exposure To Braf and Pi3K Inhibitors With Chemotherapeutic Agents
Egyhazi S; Azimi A; Ghasghgaei S; Stolt MF; Johansson CH; Hansson J
Conference publication: ANNALS OF ONCOLOGY. 2012;23:27
PROTEOMICS AND GENE EXPRESSION PROFILING OF MELANOMA CHEMOTHERAPY RESPONSE IN TUMORS
Johansson CH; Azimi A; Pernemalm M; Pawitan Y; Stolt MF; Lazar V; Lundeberg J; Lehtio J; Egyhazi S; Hansson J
Conference publication: ANNALS OF ONCOLOGY. 2012;23:23
EFFECTS OF COMBINED EXPOSURE TO BRAF AND PI3K INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS
Egyhazi S; Azimi A; Ghasghgaei S; Stolt MF; Johansson CH; Hansson J
Conference publication: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):8551
A gene expression profile associated with clinical outcome in stage III melanoma.
Falkenius J; Lindberg J; Johansson H; Frostvik-Stolt M; Lundeberg J; Hansson J; Egyhazi S
Conference publication: CANCER RESEARCH. 2011;71:3495
Targeted therapies in melanoma - in vitro effects of single and combined drug treatment
Azimi A; Egyhazi S; Johansson C; Hansson J
Letter: JOURNAL OF INVESTIGATIVE DERMATOLOGY. 2010;130(2):618-620
Coexisting NRAS and BRAF Mutations in Primary Familial Melanomas with Specific CDKN2A Germline Alterations
Jovanovic B; Egyhazi S; Eskandarpour M; Ghiorzo P; Palmer JM; Scarra GB; Hayward NK; Hansson J
Conference publication: CANCER RESEARCH. 2009;69
Investigating the role of microRNA-211 in the pathogenesis of metastatic melanoma
Caramuta S; Egyhazi S; Rodolfo M; Hansson J; Catharina L; Lui W-O
Review: MOLECULAR ONCOLOGY. 2008;1(4):395-405
Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
Platz A; Egyhazi S; Ringborg W; Hansson J
Conference publication: ANNALS OF ONCOLOGY. 2008;19:243
SHARED REGIONS OF DECREASED DNA COPY NUMBERS IN NRAS AND BRAF MUTATED MELANOMAS
Jovanovic B; Egyhazi S; Hansson J
Corrigendum: CANCER RESEARCH. 2008;68(4):1245
The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007)
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Capeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Conference publication: PIGMENT CELL AND MELANOMA RESEARCH. 2008;21(2):285
Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma
Hansson J; Jovanovic B; Krockel D; Linden D; Nilsson B; Egyhazi S
Conference publication: MELANOMA RESEARCH. 2007;17(1):a10-a11
INV 22 Drug resistance mechanisms
Egyhazi S
Conference publication: MELANOMA RESEARCH. 2007;17(1):a1-a2
INV 3 Molecular genetics of melanoma predisposition
Hansson J; Magnusson V; Tuominen R; Egyházi S; Linden D
Conference publication: MELANOMA RESEARCH. 2007;17(1):a18-A19
P-03 CCND1 A870G polymorphism and age of onset of melanoma
Egyházi S; Platz A; Grafström E; Tuominen R; Magnusson V; Hansson J
Conference publication: MELANOMA RESEARCH. 2007;17(1):a17-a18
P-02 NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
Egyházi S; Edlundh-Rose E; Omholt K; Mansson-Brahme E; Platz A; Hansson J; Lundeberg J
Conference publication: MELANOMA RESEARCH. 2007;17(1):a21-a22
P-11 Methylation of the O6 methylguanine-DNA methyltransferase promoter in melanoma tumors in relation to chemotherapy
Ma S; Edlundh-Rose E; Hansson J; Egyházi S
Conference publication: MELANOMA RESEARCH. 2006;16(Supplement 1):s26
Association of melanoma risk with phenotype and MC1R genotype in the Swedish population
Magnusson V; Tuominen R; Käller M; Månsson-Brahme E; Ahmadian A; Egyhazi S; Linden D; Sjöberg K; Lundeberg J; Hansson J
Conference publication: MELANOMA RESEARCH. 2006;16(Supplement 1):s61-s62
Amplification of the cyclin D1 locus 11q13 in melanoma metastases: association to cyclin D1 protein expression
Tuominen R; Grafström E; Egyhazi S
Conference publication: CANCER RESEARCH. 2006;66(8)
Array comparative genomic hybridization (aCGH)-based support vector machines used to determine genetic aberrations that correlate with either BRAF or NRAS mutations in melanoma tumors and cell lines
Zaks TZ; Greshock JD; Medina CA; Ward R; Egyhazi S; Nathanson K; Weber BL
Conference publication: CANCER RESEARCH. 2006;66(8)
Methylation status of the MGMT promoter in melanoma tumors in relation to protein expression and clinical response to chemotherapy
Ma S; Edlundh-Rose E; Hansson J; Lundeberg J; Egyhazi S
Conference publication: MELANOMA RESEARCH. 2004;14(4):a21-a22
P-15 Activating NRAS or BRAF mutations in combination with INK4 deletions are common in melanoma tumors
Hansson J; Grafström E; Omholt K; Egyházi S; Ringborg U; Platz A
Conference publication: MELANOMA RESEARCH. 2004;14(4):a11
24 Mutational analysis and gene expression profiling in malignant melanoma: implications for therapy
Hansson J; Huang F; Mashyekhi K; Omholt K; Jovanovic B; Sakko AJ; Egyhazi S; Frostvik M; Shaw P; Ringborg U
Letter: CLINICAL CHEMISTRY. 2004;50(5):975-976
Proteinase K added to the extraction procedure markedly increases RNA yield from primary breast tumors for use in microarray studies
Egyházi S; Bjöhle J; Skoog L; Huang F; Borg AL; Stolt MF; Hägerström T; Ringborg U; Bergh J
Conference publication: BREAST CANCER RESEARCH AND TREATMENT. 2002;76:S29
Microarray studies on a population based breast cancer cohort - search for gene profiles with prognostic and predictive value.
Bjohle J; Pawitan Y; Skoog L; Shaw P; Amler L; Humphreys K; Huang F; Egyhazi S; Borg AL; Hagerstrom T; Wedren S; Sandelin K; Hall P; Bergh J
Conference publication: AMERICAN JOURNAL OF HUMAN GENETICS. 2001;69(4):418
Novel O6-methylguanine-DNA methyltransferase single nucleotide polymorphisms (SNPs) detected among healthy individuals from the Swedish normal population.
Platz A; Ma S; Smoczynski K; Hansson J; Ringborg U; Egyhazi S
Conference publication: MELANOMA RESEARCH. 1999;9(3):329
P16 Novel polymorphisms in codons 143 and 178 in the O6-methylguanine-DNA methyltransferase gene in malignant melanoma
Egyházi S; Platz A; Smoczynski K; Ringborg U
Conference publication: MELANOMA RESEARCH. 1997;7(Supplement 1):s115
Analysis of O6-methylguanine-DNA methyltransferase in fine needle biopsies of human melanoma metastases
Hansson J; Egyhazi S; Margison G; Ringborg U
Conference publication: MELANOMA RESEARCH. 1997;7(2):161
17 Drug resistance factors in malignant melanoma
Hansson J; Egyházi S; Jungnelius U; Ringborg U
Thesis / dissertation: 1996
Studies of resistance factors against chloroethylnitrosourea drugs in malignant tumor cells
Egyházi, Suzanne
Other: BRITISH JOURNAL OF CANCER. 1995;71(1):37-39
O-6-METHYLGUANINE-DNA METHYLTRANSFERASE ACTIVITIES IN BIOPSIES OF HUMAN-MELANOMA TUMORS
EGYHAZI S; HANSSON J; RINGBORG U
Show more

Grants

Translational studies on cutaneous malignant melanoma
Konung Gustaf V:s Jubileumsfond
1 January 2021 - 31 December 2022
Translational studies on cutaneous malignant melanoma
Konung Gustaf V:s Jubileumsfond
1 January 2018 - 31 December 2020
Clinical and molecular genetic studies of malignant melanoma
Konung Gustaf V:s Jubileumsfond
1 January 2015
Molecular predictive factors for durable response of drugs targeting the MAPK pathway in melanoma
Swedish Research Council
1 January 2014 - 31 December 2016
Explore the effect of inflammation proteins on clinical outcome to treatment with anti-PD1 in metastatic cutaneous melanoma
Karolinska Institutet
New combination therapeutic strategy by targeting MET and EGFR/HER2 in malignant melanoma
Karolinska Institutet

About me

Articles

All other publications

Grants

News from KI

Events from KI